European Journal Of Haematology,
Год журнала:
2023,
Номер
112(3), С. 367 - 370
Опубликована: Окт. 26, 2023
Abstract
Objectives
To
evaluate
whether
low‐dose
belantamab
mafodotin
(B‐MAF)
dosing
results
in
lower
toxicity
and
better
overall
outcome.
Methods
We
retrospectively
evaluated
nine
consecutive
patients
treated
with
(1.9
mg/kg)
B‐MAF.
Results
The
median
age
was
70
years.
Most
were
penta‐refractory.
Ocular
observed
77.7%.
Adverse
events
resulting
treatment
delays
recorded
9
out
of
124
cycles
being
given.
Overall
response
rate
66%
(6/9),
all
responding
achieved
very
good
partial
or
better.
Within
a
follow‐up
12
(range
0.5–13.8)
months,
progression‐free
survival
14
(CI95%
6–22)
20
(95%CI
0–41)
respectively.
Conclusion
Low‐dose
B‐MAF
regimen
showed
high‐efficacy
low‐toxicity
profile.
Blood Cancer Journal,
Год журнала:
2025,
Номер
15(1)
Опубликована: Март 10, 2025
Abstract
While
initial
trials
led
to
the
accelerated
approval
of
belantamab
mafodotin,
a
BCMA-directed
antibody-drug
conjugate,
confirmatory
failed
establish
benefit
from
this
therapy
for
patients
with
relapsed
refractory
multiple
myeloma
(RRMM),
eventually
leading
its
withdrawal
commercial
use.
With
an
imminent
as
effective
combination
therapy,
seen
in
recent
randomized
trials,
we
report
real-world
clinical
outcomes
mafodotin
81
RRMM
patients.
median
5
(range
2–15)
prior
lines
92,
45,
and
15%
were
triple-class
refractory,
penta-class
BCMA-refractory.
More
than
half
(57%)
had
high-risk
cytogenetics,
37%
extramedullary
disease
(EMD),
67%
would
have
been
considered
ineligible
DREAMM-2
trial.
The
best
overall
response
(ORR)
complete
rates
40.0
15.0%,
respectively.
ORRs
lower
EMD,
BCMA-refractory,
penta-refractory
at
23,
17,
24%,
All-grade
ocular
toxicity
was
69%
patients,
grade
3+
events
43%.
Grade
hematological
toxicities
included
neutropenia
(20%),
anemia
(28%),
thrombocytopenia
(31%).
follow-up
11.3
(0.3–44.6)
months
entire
population,
PFS
OS
(1–20)
12
(3–28)
months,
Presence
EMD
only
predictor
both
on
multivariable
analysis.
Compared
pivotal
trial
despite
several
features,
demonstrated
comparable
efficacy
safety
patient
population.
eJHaem,
Год журнала:
2024,
Номер
5(3), С. 485 - 493
Опубликована: Апрель 30, 2024
Abstract
Belantamab
mafodotin
is
the
first‐in‐class
antibody‐drug
conjugates
targeting
B‐cell
maturation
antigen
to
have
demonstrated
effectiveness
in
triple‐class
refractory
multiple
myeloma
(TCR‐MM)
patients.
We
performed
a
retrospective
study
including
78
TCR
patients,
with
at
least
four
prior
lines
of
therapy
(LOTs),
who
received
belantamab
within
named
patient
program
and
expanded
access
Italy
between
2020
2022.
Median
age
was
65
years
(range
42–86
years),
ECOG
performance
status
≥1
45%
Overall,
clinical
benefit
obtained
36
out
74
evaluable
patients
(49%),
43%,
28%,
13.5%
achieving
partial
response,
very
good
complete
respectively.
After
median
follow‐up
12
months
6–21
months),
duration
progression‐free
survival
(PFS),
overall
(OS)
were
14,
5.5,
months,
Age
>70
years,
response
associated
longer
PFS
OS.
Keratopathy
occurred
58%
(G3
2.5%),
corneal
symptoms
32%
1.2%)
reduction
visual
acuity
14%.
Grade
3
thrombocytopenia
9%
Only
3%
discontinued
because
side
effects.
This
real‐life
significant
durable
responses
TCR‐MM
LOTs,
otherwise
ineligible
for
novel
immunotherapies.
Leukemia & lymphoma/Leukemia and lymphoma,
Год журнала:
2024,
Номер
unknown, С. 1 - 13
Опубликована: Ноя. 18, 2024
New
generation
therapies
such
as
bispecific
antibodies
(BsAb),
chimeric
antigen
receptor
T-cell
therapy
(CAR
T)
and
antibody-drug
conjugates
(ADC)
have
revolutionized
the
treatment
of
relapsed/refractory
multiple
myeloma
(RRMM).
However,
there
is
emerging
evidence
increased
infection
risk
associated
with
these
treatments
in
clinical
trials
observational
settings.
This
may
be
mediated
by
on-target,
off-tumor
side
effects
cytokine
release
syndrome,
hypogammaglobulinaemia
cytopenias,
disease-related
humoral
impairment
consequences
previous
lines
treatment.
While
bacterial
viral
pathogens
predominate,
reactivation
latent
opportunistic
infections
also
warrant
attention.
review
characterizes
epidemiology
novel
for
RRMM
to
guide
prophylaxis
antimicrobial
prescribing
this
patient
population
highlights
future
areas
focus
inform
ongoing
prevention
strategies.
Research Square (Research Square),
Год журнала:
2024,
Номер
unknown
Опубликована: Ноя. 19, 2024
Abstract
While
initial
trials
led
to
the
accelerated
approval
of
belantamab
mafodotin,
a
BCMA
directed
antibody
drug
conjugate,
confirmatory
failed
establish
benefit
from
this
therapy
for
patients
with
relapsed
refractory
multiple
myeloma
(RRMM),
eventually
leading
its
withdrawal
commercial
use.
With
an
imminent
as
effective
combination
seen
in
recent
randomized
trials,
we
report
real-world
clinical
outcomes
mafodotin
81
RRMM
patients.
median
5
(range
2–15)
prior
lines
therapy,
92%,
45%,
and
15%
were
triple-class
refractory,
penta-class
BCMA-refractory.
More
than
half
(57%)
had
high-risk
cytogenetics,
37%
extramedullary
disease
(EMD),
67%
would
have
been
considered
ineligible
DREAMM-2
trial.
Best
overall
response
(ORR)
complete
rates
40.0%
15.0%,
respectively.
ORRs
lower
EMD,
BCMA-refractory
penta-refractory
at
23%,
17%,
24%,
All
grade
ocular
toxicity
was
69%
3
+
events
43%.
Grade
hematological
toxicities
included
neutropenia
(20%),
anemia
(28%),
thrombocytopenia
(31%).
follow-up
11.3
(0.3–44.6)
months
entire
population,
PFS
OS
(1–20)
12
(3–28)
months,
Presence
EMD
only
predictor
both
on
multivariable
analysis.
Compared
pivotal
trial
despite
several
features,
demonstrated
comparable
efficacy
safety
patient
population.
